Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma

NCT06413498 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT06413498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06413498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Kite, A Gilead Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 23, 2024
Completion date
July 31, 2031
Enrollment
452 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma